Royalty Report: Drugs, Disease, Alzheimer’s disease – Collection: 266151

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Disease
  • Alzheimer’s disease
  • Parkinsons Disease

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 266151

License Grant
The Company entered into a Research Grant and License Agreement with an Undisclosed Stockholder of the Company. The Agreement requires the Company to pay royalties to the stockholder.
License Property
The Company’s lead compound, COR388, is beginning Phase 2/3 development, targeting a specific, infectious pathogen found in the brain of Alzheimer’s patients and tied to neurodegeneration and neuroinflammation in animal models.  The compound is being developed for treatment of Alzheimers Disease.
Field of Use
This agreement pertains to the drug industry.  The IP will be used to try and create a disease-modifying therapeutic approach to Alzheimer’s and other degenerative diseases.

IPSCIO Record ID: 262864

License Grant
Under the collaboration agreement, the German Company grants the partner an exclusive license to certain therapeutic antibodies for specific targets and receives license fees, research and development funding, milestone payments and/or, if a product is approved for marketing, sales royalties in return.  Through the Partnered Discovery Program, the Company generates antibody candidates for partners in the pharmaceutical and biotechnology industries. A HuCAL antibody targeting amyloid beta that is in phase 3 clinical testing by our partner for the treatment of Alzheimer’s disease is Gantenerumab.
License Property
Gantenerumab is a HuCAL antibody directed against amyloid beta (Aß) that is being developed for the treatment of Alzheimer’s disease. Aß denotes a group of peptides that are crucially involved in Alzheimer’s disease as the main component of the amyloid plaques found in the brains of Alzheimer’s patients. In phase 1 clinical trials, gantenerumab has been shown to reduce brain amyloid in mild-to-moderate Alzheimer’s disease patients. Gantenerumab is being investigated in several clinical studies to see if there is a positive effect from intervening at an early stage in the disease’s progression.
Field of Use
Gantenerumab is an investigational immunotherapy being developed to treat Alzheimer’s disease by potentially reducing beta-amyloid plaques in the brain.

IPSCIO Record ID: 294263

License Grant
Commercial Licenses to Licensee: Subject to the terms and conditions of this Agreement, Licensor hereby grants to Licensee (i) an exclusive worldwide, royalty-bearing license during the Agreement Term, including the right to sublicense, under the Licensor IP and Joint IP to make, use, import, sell and offer to sell Products and (ii) a non-exclusive, worldwide perpetual, royalty-free license, with the right to sublicense, under the Licensor IP to make, use, import, sell, and offer to sell biomarkers and diagnostics relating to Products. The license granted shall survive the expiration or termination of the Agreement Term.
License Property
The goal of the Collaboration is to discover compounds directed against the pathology mediated by or directly associated with the protein tau in Alzheimers disease (Compounds) and to develop such Compounds as pharmaceutical products (Products).

Combination Product means any pharmaceutical product which contains one or more pharmacologically or therapeutically active compound(s), product(s) and/or ingredient(s) in addition to Product.

Licensor will remain the sole owner of or otherwise shall continue to control rights in all IP relating to any and all Materials, information, plans or methods, except for Products, that may be disclosed to Licensee or developed solely by Licensor, or licensed to Licensor prior to or separate from performance of the Collaboration (Licensor Existing IP).  

All IP conceived in the execution of the Collaboration solely by Licensor, except for Product-related IP, will be owned by Licensor (Licensor New IP)

All IP in the Field conceived in the execution of the Collaboration jointly by Licensor and Licensee, except for Product-related IP, will be owned jointly by Licensor and Licensee (Joint IP), provided that all IP in the Field created solely by any staff at  Party A will be owned by Party A and licensed to Licensor under the Party A Agreements, and will be considered part of the Licensor IP licensed to Licensee under this Agreement.

Field of Use
The field in research and development of Compounds in the field of the following neurodegenerative diseases: Alzheimers disease; frontotemporal dementia; Pick s disease; and progressive supranuclear palsy.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.